B GROUP INC
Q2 2025 Form 13-F
DALLAS, KANSAS
CIK 0002043476
· Institutional investment manager
$129.9M Reported Value Total
Reported value
$129.9M
Quarter over quarter
+7.5%
Holdings
15
Top-10 concentration
89.6%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
David Chang
Chief Compliance Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2025 13F record
Q2 2025 13F filing summary
| Period of report | June 30, 2025 |
|---|---|
| Filed | August 14, 2025 |
| Form | 13F-HR |
| Reported value | $129.9M |
| Positions | 15 |
| Change in reported value | +11.3% |
| New positions | 0 |
| Exited positions | 2 |
| Position turnover | 11.8% |
| Top-10 concentration | 89.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
18 | $213.0M |
|
Q1 2026 13F
Filed May 15, 2026
|
20 | $134.9M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
15 | $135.4M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
17 | $135.9M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
15 | $129.9M |
|
Q1 2025 13F
Filed May 15, 2025
|
17 | $116.7M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
18 | $163.6M |
Top 17 holdings · Q2 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ADMA ADMA BIOLOGICS INC | $42.2M | 32.48% |
| 2 | INSM INSMED INC | $15.6M | 12.01% |
| 3 | ZLAB ZAI LAB LTD | $14.0M | 10.77% |
| 4 | AKRO AKERO THERAPEUTICS INC | $12.4M | 9.55% |
| 5 | LLY P ELI LILLY & CO | $11.7M | 9.0% |
| 6 | CLLS CELLECTIS S A | $5.0M | 3.82% |
| 7 | TSHA TAYSHA GENE THERAPIES INC | $4.2M | 3.2% |
| 8 | RARE ULTRAGENYX PHARMACEUTICAL IN | $4.0M | 3.08% |
| 9 | SGHT SIGHT SCIENCES INC | $3.8M | 2.96% |
| 10 | AURA AURA BIOSCIENCES INC | $3.6M | 2.76% |
| 11 | ASMB ASSEMBLY BIOSCIENCES INC | $3.4M | 2.64% |
| 12 | IOVA IOVANCE BIOTHERAPEUTICS INC | $2.6M | 1.99% |
| 13 | RARE C ULTRAGENYX PHARMACEUTICAL IN | $2.5M | 1.89% |
| 14 | APGE APOGEE THERAPEUTICS INC | $1.5M | 1.17% |
| 15 | PRAX PRAXIS PRECISION MEDICINES I | $1.5M | 1.13% |
| 16 | SYRE SPYRE THERAPEUTICS INC | $1.2M | 0.92% |
| 17 | ORKA ORUKA THERAPEUTICS INC | $840.8K | 0.65% |
Values as reported on the Q2 2025 Form 13F. Every position is in the holdings table below.